@article{070d01b2fc314d6191a1c277d1dc1da8,
title = "Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study",
abstract = "A joint meeting of the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) was held in London on September 30 and October 1, 2017. The goals of the meeting were to identify areas of broad agreement and disagreement, develop consensus, and determine future directions to ultimately reduce the burden, morbidity, and mortality of alcohol-related liver disease (previously termed alcoholic liver disease). The specific aims of the meeting were to identify unmet needs and areas for future investigation, in order to reduce alcohol consumption, develop markers for diagnosis and prognosis of disease, and create a framework to test novel pharmacological agents with pre-specified treatment endpoints.",
keywords = "ALD, Alcohol, Biomarkers, Clinical trials, Endpoints, Epidemiology, Public health, Unmet needs",
author = "Mark Thursz and Kamath, {Patrick S.} and Philippe Mathurin and Gyongyi Szabo and Shah, {Vijay H.}",
note = "Funding Information: M.T. reports grants from Novartis , Gilead and Vital Therapeutics , and personal fees from Affimune outside the submitted work. P.M. reports personal fees from Verlyx and Gilead during the study, and personal fees from Gilead, Abbvie , MSD , Bayer Healthcare , Intercept , Sanofi and Verlyx outside the submitted work. V.S. reports personal fees from Enterome, France; Vital Therapies, USA; Novartis Pharma, Switzerland; Durect Corporation, USA; Merck Research Laboratories, USA; Afimmune Ltd., Ireland outside the submitted work. G.S. consults for Terra Firma, Carlos Foundation, Glympse Bio, Quest Diagnostic, Arrow Diagnostic, GLG, Salix, Tobira and Allergan. G.S. has received funding from NIH-NIAAA, Gilead, Genfit, University of Florida, Intercept, Allergan, Novartis, SignaBlok and Shire. P.K. has no conflicts of interest in relation to this manuscript. Funding Information: M.T. reports grants from Novartis, Gilead and Vital Therapeutics, and personal fees from Affimune outside the submitted work. P.M. reports personal fees from Verlyx and Gilead during the study, and personal fees from Gilead, Abbvie, MSD, Bayer Healthcare, Intercept, Sanofi and Verlyx outside the submitted work. V.S. reports personal fees from Enterome, France; Vital Therapies, USA; Novartis Pharma, Switzerland; Durect Corporation, USA; Merck Research Laboratories, USA; Afimmune Ltd., Ireland outside the submitted work. G.S. consults for Terra Firma, Carlos Foundation, Glympse Bio, Quest Diagnostic, Arrow Diagnostic, GLG, Salix, Tobira and Allergan. G.S. has received funding from NIH-NIAAA, Gilead, Genfit, University of Florida, Intercept, Allergan, Novartis, SignaBlok and Shire. P.K. has no conflicts of interest in relation to this manuscript. Publisher Copyright: {\textcopyright} 2019 European Association for the Study of the Liver, American Association for the Study of Liver Diseases",
year = "2019",
month = mar,
doi = "10.1016/j.jhep.2018.10.041",
language = "English (US)",
volume = "70",
pages = "521--530",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "3",
}